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Abstract
Purpose Systematic review and meta-analysis comparing endoscopic and microscopic transsphenoidal surgery for Cushing’s 
disease regarding surgical outcomes (remission, recurrence, and mortality) and complication rates. To stratify the results 
by tumor size.
Methods Nine electronic databases were searched in February 2017 to identify potentially relevant articles. Cohort studies 
assessing surgical outcomes or complication rates after endoscopic or microscopic transsphenoidal surgery for Cushing’s 
disease were eligible. Pooled proportions were reported including 95% confidence intervals.
Results We included 97 articles with 6695 patients in total (5711 microscopically and 984 endoscopically operated). Overall, 
remission was achieved in 5177 patients (80%), with no clear difference between both techniques. Recurrence was around 
10% and short term mortality < 0.5% for both techniques. Cerebrospinal fluid leak occurred more often in endoscopic sur-
gery (12.9 vs. 4.0%), whereas transient diabetes insipidus occurred less often (11.3 vs. 21.7%). For microadenomas, results 
were comparable between both techniques. For macroadenomas, the percentage of patients in remission was higher after 
endoscopic surgery (76.3 vs. 59.9%), and the percentage recurrence lower after endoscopic surgery (1.5 vs. 17.0%).
Conclusions Endoscopic surgery for patients with Cushing’s disease reaches comparable results for microadenomas, and 
probably better results for macroadenomas than microscopic surgery. This is present despite the presumed learning curve of 
the newer endoscopic technique, although confounding cannot be excluded. Based on this study, endoscopic surgery may 
thus be considered the current standard of care. Microscopic surgery can be used based on neurosurgeon’s preference. Endo-
crinologists and neurosurgeons in pituitary centers performing the microscopic technique should at least consider referring 
Cushing’s disease patients with a macroadenoma.
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Introduction
Cushing’s disease is caused by an adrenocorticotropic hor-
mone (ACTH)-secreting pituitary adenoma, with an esti-
mated incidence of 1.2–2.4 per million each year [1]. The 
resulting excess of glucocorticoids induces insulin resist-
ance, dyslipidemia, central obesity, hypercoagulability, 
and increases the risk of osteoporosis, hypertension, and 
neuropsychiatric disorders [2, 3]. First-choice treatment 
for Cushing’s disease is transsphenoidal pituitary surgery, 
with selective adenoma removal [4]. Despite biochemical 
cure, mortality risk in Cushing’s disease patients remains 
increased [5].
Two main techniques have been used for transsphenoi-
dal pituitary surgery: microscopic and endoscopic surgery. 
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Furthermore, the microscopic and endoscopic techniques 
have been used in combination, in which the endoscope 
was used to visually confirm findings of the microscope. 
The microscopic technique was the established method to 
perform transsphenoidal surgery, until the first reports on 
endoscopic pituitary surgery were published, starting in 
1992 [6]. With the operating microscope, intraoperative 
differentiation of pathologic tissue from normal tissue is 
achieved by providing three-dimensional vision in a direct 
line to the pituitary [7, 8]. Endoscopic pituitary surgery 
provides a broader field of vision using endoscopes with 
various angles in close proximity to the pituitary, how-
ever losing the three-dimensional vision and thus depth 
perception [6, 8]. From the introduction of the endoscope 
in transsphenoidal surgery, most surgical centers have cho-
sen for microscopy or endoscopy. Only few small cohort 
studies have compared the microscopic and endoscopic 
surgical techniques in Cushing’s disease performed in the 
same center [9–12]. No clear differences in remission rate 
or surgical morbidity between microscopic and endoscopic 
surgery could be shown. However, the studies had only 
limited statistical power [9].
Several systematic reviews have compared endoscopic 
and microscopic surgical techniques in a heterogeneous 
population of patients with various pituitary adenomas. 
These studies have found a reduced rate of some complica-
tions (postoperative diabetes insipidus, rhinological com-
plications), but an increased rate of other complications 
(vascular complications, cerebrospinal fluid leak, anterior 
pituitary hormone deficiency) for the endoscopic technique 
[8, 13, 14]. These differences in outcomes may partially 
be explained by the surgeon’s attempt for a more radical 
tumor excision with the newer endoscopic technique with 
better vision, by the larger proportion of more challenging 
macroadenomas and re-operations reported in literature, and 
by improved rhinological care by an otolaryngologist after 
endoscopic surgery [8, 13, 14]. Until now, no systematic 
review has been published comparing the microscopic to the 
endoscopic surgical technique in Cushing’s disease. Con-
vincing evidence supporting the choice for one of both tech-
niques in the treatment of Cushing’s disease, either based on 
treatment results or complication rate, is thus lacking.
Study aims
The primary aims of this systematic review were to compare 
remission and recurrence rate, and mortality, after micro-
scopic vs. endoscopic transsphenoidal pituitary surgery for 
Cushing’s disease. Secondary study aims were to compare 
complication rates, remission and recurrence rates stratified 




Randomized controlled trials and cohort studies in Cush-
ing’s disease assessing outcomes after endoscopic or 
microscopic transsphenoidal surgery were eligible. Studies 
describing endoscope-assisted microscopic surgery were 
considered microscopic surgery. Single-arm studies as well 
as direct comparisons were considered, mainly because we 
did not expect many direct comparisons in a single cohort. 
Study outcomes of interest were remission rate, recurrence 
rate, short and long term mortality risk, and complications 
of surgery. Studies reporting outcomes after primary as well 
as after repeat transsphenoidal surgery were eligible. Studies 
reporting < 10 patients with Cushing’s disease per treatment 
group were excluded to minimize the risk of selection bias. 
Articles were also excluded if the study included children 
only, if the study did not clearly report which surgery type 
was performed, or if no distinction between surgery types 
was made in the analysis. Articles including patients with 
selective adenomectomy as well as partial or total hypophy-
sectomy were included as long as total hypophysectomy did 
not exceed 5%. If described separately, patients with total 
hypophysectomy were excluded from analyses. If multiple 
articles described (partially) the same population, the arti-
cle with the largest cohort was included per analysis. Arti-
cles irretrievable online were requested by contacting the 
authors. Articles still irretrievable, but with sufficient data 
mentioned in the abstract for reliable eligibility assessment 
and data extraction, were included. Only articles in English 
were considered.
Search strategy
To identify potentially relevant articles, PubMed, Embase, 
Web of Science, COCHRANE Library, CENTRAL, Emcare, 
LWW, ScienceDirect and Wiley were systematically 
searched in February 2017 in cooperation with a special-
ized librarian (see Online Resource 1 for the complete search 
strategy). References of included articles were searched and 
the search strategy was manually extended in PubMed with 
the search term ‘pituitary adenoma’ to find more potentially 
eligible studies.
Data extraction
All identified articles were imported in endnote 8 (Thom-
son Reuters, Philadelphia, PA, USA). Studies were screened 
by title and abstract and potentially relevant articles were 
reviewed in detail to assess eligibility. Potentially relevant 
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articles were screened and reviewed by two reviewers inde-
pendently and disagreement was solved by consensus. The 
meta-analysis of observational studies in epidemiology 
(MOOSE) guidelines were used for reporting [15].
Risk of bias assessment
For risk of bias analysis we used a component approach. 
Risk of bias was assessed by two independent reviewers for 
all included studies using the following components, which 
could potentially bias a reported association between surgi-
cal technique and outcome:
1. Inclusion of patients (consecutive inclusion or a random 
sample is considered low risk of bias)
2. Loss to follow-up (< 5% is considered low risk of bias)
3. Criteria for diagnosis of Cushing’s disease (see below)
4. Clear reporting of criteria for main study outcome. For 
most studies the main outcome is remission of Cushing’s 
disease. If remission is not a study outcome, studies will 
be checked for reporting criteria for their primary study 
outcome, most often one or more complications of treat-
ment.
As criteria for diagnosis of Cushing’s disease vary widely 
over time and per study center, and study outcomes also vary 
per included article, mentioning the criteria for diagnosis 
and study outcome is considered a low risk of bias. Classifi-
cation of interventions is not considered in this risk of bias 
analysis, because the interventions of interest are one-time 
procedures and therefore unlikely to be misclassified.
Risk of bias analysis was used to explore potential hetero-
geneity. As most studies did not compare the two surgical 
techniques directly, confounding was not judged at the study 
level, but was assessed by comparing baseline character-
istics between microscopically and endoscopically treated 
patients. Variables influencing the choice of treatment as 
well as co-interventions that could affect treatment outcome 
are reported.
Study endpoints
The main outcomes of this study were the percentage of 
patients reaching remission, the recurrence rate, and the 
short term mortality risk after microscopic and endoscopic 
transsphenoidal pituitary surgery for Cushing’s disease. Sec-
ondary outcomes were complication rates, rates of remission 
and recurrence stratified by tumor size, and the percentage 
of patients to reach remission after a repeat transsphenoidal 
surgical procedure. Because of the low number of studies 
with direct comparisons, percentages were reported per sur-
gical technique.
Remission was considered direct postoperatively (until 
6 months post-surgery). Hydrocortisone dependency was 
calculated as a percentage of the total patient population to 
maintain comparability with remission rate. Disease recur-
rence was estimated as percentage of the patients with ini-
tial remission. Mortality risk was analysed for short-term 
mortality (< 3 months after surgery). Long-term mortality 
risk (≥ 3 months after surgery) was not analysed, as time 
since surgery was often unclear. Articles reporting mortality 
without mentioning time since surgery were excluded from 
mortality analyses.
The following complications were assessed: cerebrospinal 
fluid leak (CSF leak), meningitis, syndrome of inappropriate 
antidiuretic hormone secretion (SIADH), anterior pituitary 
hormone deficiency, thromboembolism, bleeding, transient 
diabetes insipidus, permanent diabetes insipidus, and psy-
chopathology. If an article described diabetes insipidus with-
out specifying the duration, it was excluded from diabetes 
insipidus analyses.
Statistical analysis
Percentages were pooled in a random-effects logistic regres-
sion model if there were ≥ 5 articles per analysis. A fixed-
effects model was used for analyses with < 5 studies. The 
Freeman-Tukey arcsine transformation was used to stabilize 
variances, in order to prevent exclusion of studies with 0 or 
100% as outcome. All analyses were performed using Stata 
11.2 (Stata Corp., College Station, TX, USA).
Sensitivity analyses were performed to assess the poten-
tial effect of high risk of selection bias studies by excluding 
articles in which inclusion of patients was not consecutive 
or a random sample and/or loss to follow-up was ≥ 5%. Of 
note, articles not mentioning method of inclusion or loss 
to follow-up were not excluded in these sensitivity analy-
ses, as this would not leave sufficient articles for analysis 
(13 for microscopic surgery and one for endoscopic sur-
gery only). Sensitivity analyses were also performed for 
studies with a study period starting from the year 2000 or 
later, to assess the potential cohort effect of calendar year 
of surgery. Finally, sensitivity analyses were performed for 
studies reporting specific criteria for diagnosis of Cush-
ing’s disease (pituitary imaging or petrosal sinus sampling, 
and at least one of the following laboratory measurements 
or tests: increased morning serum cortisol, increased 24-h 
urinary free cortisol, increased midnight salivary cortisol, 
no suppression of cortisol after a low dose dexamethasone 
test combined with a non-suppressed ACTH) to increase 
reliability of including only Cushing’s disease patients, as 
well as for studies using at least a low dose dexamethasone 
test in the determination of remission status to increase test 
homogeneity, and for studies assessing remission status 3–6 
months postoperatively, as this is a more reliable timeframe 
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The initial search identified 932 articles. Searching through 
references of included articles and manually extending the 
search in PubMed with the search term ‘pituitary adenoma’ 
identified another 16 articles, thereby yielding a total of 948 
articles. After screening the articles by title and abstract, 
685 articles were excluded, leaving 263 articles for detailed 
review. Reasons for exclusion are summarized in Fig. 1. 
There were 97 articles included in this review, two of which 
based on abstract only [17, 18].
Study characteristics (online resource 2)
No RCTs were performed comparing microscopic to endo-
scopic surgery. There were 71 studies reporting on micro-
scopic surgery only [4, 7, 17, 19–86], 22 studies reporting 
on endoscopic surgery only [18, 87–107], and four studies 
from four different centers reporting on both microscopic 
and endoscopic surgery in the same center [9–12]. Stud-
ies reporting on both techniques were entered twice in the 
tables and analyses, separately for each of the techniques. 
Articles were published between 1978 and 2017 for micro-
scopic surgery and from 2001 to 2017 for endoscopic sur-
gery. Two included articles reported only results for patients 
after repeat transsphenoidal surgery [65, 82]. A total of 5711 
patients were included for the microscopic technique, and 
984 patients for the endoscopic technique.
Risk of bias assessment
Detailed risk of bias assessment per included article is shown 
in Online Resource 3. Reported loss to follow-up [reported 
in 35 studies (36%)] ranged from 0 to 26.9%. Inclusion of 
consecutive patients or a random sample of patients was 
explicitly stated in 73 articles (75%). There were 80 arti-
cles (82%) that reported the criteria for Cushing’s disease 
diagnosis, or that referred to the article in which the exact 
criteria were published. Criteria for main study outcome 
were reported in 88 articles (91%). Remission of Cushing’s 
disease was the main study outcome in 83 of these 88 arti-
cles (94%).
Differences in baseline characteristics (confounding) are 
likely as treatment assignment was dependent on calendar 
year of surgery and center. There were only three articles 
describing both techniques in the same center and in the 
same calendar period (see Online Resource 2). Furthermore, 
there was a slight difference in average age at treatment 
(microscopy 21.5–50 years; endoscopy 31.9–55.7 years) 
and in percentage female (microscopy 67–93%; endoscopy 
57–95%). Co-interventions that could influence treatment 
outcome are reported per article in Online Resource 3. 
Nine included articles (9%) explicitly reported that no co-
interventions were used, 20 articles (21%) reported use of 
co-interventions before or shortly after treatment in part of 
their included patients. The remaining 68 articles (70%) did 
not report on co-interventions.
Study outcomes
For a total of 91 study groups (87 articles), remission was 
the primary outcome of interest. Overall, remission was 
obtained in 80% (5177/6484) of patients. There were 48 
articles reporting a (short and/or long term) mortality rate, 
and 60 articles reported the rate of, at least one, complica-
tion. For details of study outcomes at the individual study 
level, see Online Resource 4.
Pooled proportions of surgical outcomes: remission, 
recurrence, mortality, and remission after repeat surgery 
(Fig. 2; Table 1)
The percentage remission was similar for microscopically 
and endoscopically treated patients, both reaching around 
80% remission. Hydrocortisone dependency was seen 
in 39.3% (95% confidence interval [CI] 23.5–56.4%) of 
patients after microscopic surgery and in 33.5% (95% CI 
13.3–57.3%) after endoscopic surgery. Recurrence of dis-
ease occurred in around 10% of patients after both types of 
surgery. Average follow-up duration for studies reporting 
on disease recurrence was 1.0–15.4 years for microscopy 
and 1.4–5.9 years for endoscopy. Recurrence occurred after Fig. 1  Flow-chart of inclusion of articles in this systematic review
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an average of 6–76 months in studies using the microscopic 
technique, and after an average of 24–54 months in stud-
ies using the endoscopic technique. Short term mortality 
was 0.0% (95% CI 0.0–0.2%) for microscopic surgery and 
0.4% (95% CI 0.0–2.2%) for endoscopic surgery. The per-
centage of patients that obtained remission after a repeated 
transsphenoidal surgical procedure was 55.7% (95% CI 
43.3–67.8%) for microscopic surgery, and 42.6% (95% CI 
18.4–68.4%) for endoscopic surgery. Measurements of treat-
ment effect were consistent across individual studies, and 
spread of measurements is reflected by the 95% confidence 
interval of the outcomes of the analyses.
Pooled proportions of complications after transsphenoidal 
pituitary surgery for Cushing’s disease (Fig. 3; Table 1)
Cerebrospinal fluid leak was reported less often in patients 
after microscopic surgery [4.0% (95% CI 2.3–6.1%)], than 
after endoscopic surgery [12.9% (95% CI 5.8–22.1%)]. Fur-
thermore, SIADH, bleeding and permanent diabetes insipi-
dus were seen slightly less often in patients after microscopic 
surgery, than in patients after endoscopic surgery. Transient 
diabetes insipidus was reported more often in patients 
after microscopic surgery [21.7% (95% CI 15.0–29.3%)], 
than in patients after endoscopic surgery [11.3% (95% CI 
6.6–17.1%)]. Meningitis (around 0.4%), anterior pitui-
tary deficiency (around 10.5%), and thromboembolism 
(little over 1%), were seen in about equal percentages of 
patients, regardless of surgical technique. Psychopathology 
was reported in 0.7% (95% CI 0.0–3.1%) of patients after 
Fig. 2  Analysis of surgical outcomes of transsphenoidal surgery for 
Cushing’s disease. Bars: 95% confidence interval
Table 1  Results of meta-
analyses comparing microscopic 
and endoscopic surgery for 
Cushing’s disease
Microscopic surgery Endoscopic surgery
Estimated 
percentage
95% CI Estimated 
percentage
95% CI
Meta-analysis of surgical outcomes
 Remission 80.5 77.6–83.3 79.2 74.3–83.8
 Hydrocortisone dependency 39.3 23.5–56.4 33.5 13.3–57.3
 Recurrence 11.5 9.0–14.3 9.6 6.9–12.7
 Short term mortality 0.0 0.0–0.2 0.4 0.0–2.2
 Remission after repeat surgery 55.7 43.3–67.8 42.6 18.4–68.4
Meta-analysis of complications
 Cerebrospinal fluid leak 4.0 2.3–6.1 12.9 5.8–22.1
 Meningitis 0.6 0.1–1.3 0.1 0.0–1.0
 Syndrome of inappropriate antidiuretic 
hormone secretion
3.5 1.3–6.6 5.2 2.9–8.0
 Anterior pituitary hormone deficiency 9.4 5.1–14.8 11.5 5.7–18.8
 Thromboembolism 1.2 0.4–2.3 1.5 0.4–3.0
 Bleeding 1.9 0.7–3.5 3.7 0.8–8.3
 Transient diabetes insipidus 21.7 15.0–29.3 11.3 6.6–17.1
 Permanent diabetes insipidus 2.4 1.1–4.1 4.0 2.2–6.3
 Psychopathology 0.7 0.0–3.1 – –
Meta-analysis of surgical outcomes according to tumor size
 Remission for microadenoma 85.5 81.2–89.3 83.9 76.8–90.0
 Recurrence for microadenoma 9.8 6.8–13.2 8.1 4.3–12.8
 Remission for macroadenoma 59.9 52.0–67.6 76.3 64.3–86.7
 Recurrence for macroadenoma 17.0 5.6–31.5 1.5 0.0–6.4
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microscopic surgery. There were no articles on endoscopic 
surgery reporting on psychopathology.
Pooled proportions of remission and disease recurrence 
according to tumor size (Fig. 4; Table 1)
For microadenomas, the percentage of patients that achieved 
remission was 85.5% (95% CI 81.2–89.3%) after micro-
scopic surgery vs. 83.9% (95% CI 76.8–90.0%) after endo-
scopic surgery. Recurrence of disease occurred in 9.8% (95% 
CI 6.8–13.2%) of patients after microscopic surgery vs. 8.1% 
(95% CI 4.3–12.8%) after endoscopic surgery.
For macroadenomas, the percentage of patients that 
achieved remission was 59.9% (95% CI 52.0–67.6%) after 
microscopic surgery vs. 76.3% (95% CI 64.3–86.7%) after 
endoscopic surgery. Disease recurrence occurred in 17.0% 
(95% CI 5.6–31.5%) after microscopic surgery vs. 1.5% 
(95% CI 0.0–6.4%) after endoscopic surgery.
Sensitivity analysis
Generally, results from sensitivity analyses were similar to 
those found in the main analyses. Detailed results for sen-
sitivity analyses and the number of studies per analysis can 
be found in Online Resource 5.
Discussion
We performed a systematic review to compare surgical 
outcomes after microscopic vs. endoscopic transsphenoi-
dal pituitary surgery for Cushing’s disease. Regardless of 
surgical technique, remission rates were around 80% and 
recurrence rates around 10% after transsphenoidal surgery. 
There were no clear differences between surgical techniques 
regarding mortality, or remission rates after repeat trans-
sphenoidal surgery. Complication rates ranged from 0.1% 
(for meningitis) to 21.7% (for transient diabetes insipidus), 
with minor differences between surgical techniques. Remis-
sion and recurrence rates for microadenomas were similar 
for both surgical techniques. However, remission rate was 
higher for macroadenomas (76.3 vs. 59.9%), with a lower 
recurrence rate (1.5 vs. 17.0%) after endoscopic surgery than 
after microscopic surgery. Thus, for macroadenomas only 
there seems to be an advantage of the endoscopic over the 
microscopic surgical technique for transsphenoidal treatment 
of Cushing’s disease.
This is the first systematic review comparing microscopic 
and endoscopic transsphenoidal pituitary surgery specifi-
cally for Cushing’s disease. We found comparable remission 
and mortality rates for both surgical techniques, which is in 
line with results of meta-analyses of heterogeneous popula-
tions of various pituitary adenomas, and some small cohort 
studies comparing both techniques directly for Cushing’s 
disease [8–14]. Differences in complications rates found in 
meta-analyses of heterogeneous populations of various pitui-
tary adenomas can partially be confirmed by our analysis 
(reduced rate of transient diabetes insipidus, and increased 
rate of vascular complications and cerebrospinal fluid leak 
for the endoscopic technique) [8, 13, 14]. The increased 
rate of anterior pituitary hormone deficiency for endoscopic 
transsphenoidal surgery was not found in the present study 
[14]. The difference in remission rate between the surgical 
techniques for macroadenomas, but not microadenomas, 
is in line with the results from a cohort study on multiple 
pituitary adenomas described separately, that reported an 
advantage of the endoscopic technique for macroadenomas, 
but not for microadenomas. This difference was statistically 
Fig. 3  Analysis of complication rates after transsphenoidal surgery 
for Cushing’s disease. Bars: 95% confidence interval
Fig. 4  Analysis of surgical outcomes of transsphenoidal surgery for 
Cushing’s disease, stratified by tumor size. Bars: 95% confidence 
interval
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significant for the population as a whole, but was supported 
by differences in the same direction for all included types of 
pituitary adenoma, including Cushing’s disease [11].
In interpreting the results, the following study limitations 
need to be taken into account. Most included studies in this 
study were single-arm studies, limiting the possibilities of 
directly comparing microscopic to endoscopic transsphe-
noidal surgery. However, as treatment assignment in most 
studies was based on availability of a specific technique in 
the surgical center, for endoscopy often based on prefer-
ence of the neurosurgeons after a test period, other base-
line characteristics, such as age and gender distribution, are 
unlikely to have influenced treatment assignment largely. 
As microscopy was the established surgical technique until 
the introduction of the endoscope for transsphenoidal sur-
gery for Cushing’s disease, year of surgery varied widely for 
included studies [108]. For endoscopic surgery, a learning 
curve has been described [97, 98]. As most studies did not 
report patient level data, the effect of a potential learning 
curve per surgical center could not be analyzed in this study. 
However, to avoid measuring an effect of a collective learn-
ing curve, the earliest studies using endoscopic surgery, with 
study periods starting before the year 2000, were excluded 
in the previously mentioned sensitivity analysis.
Included studies showed heterogeneity in criteria used 
for diagnosing Cushing’s disease, both in tests used to deter-
mine remission status, and in time period after surgery for 
assessment of remission status. Sensitivity analyses showed 
generally comparable results to the main analyses. Differ-
ences are likely to have occurred because of the small num-
ber of studies included in these sensitivity analyses com-
pared to the number of studies in the corresponding main 
analyses. However, too many studies did not clearly report 
loss to follow-up, method of inclusion of patients, or both, 
preventing us from performing a sensitivity analysis exclud-
ing both articles with unclear risk of selection bias as well 
as high risk of bias, as this restriction would have resulted 
in one low bias risk article only in endoscopy. Follow-up 
duration differed between publications, which could poten-
tially lead to a bias in the analysis of recurrences, as this 
is the only truly long-term outcome. However, given that 
most recurrences occur early after initial surgery (with only 
one microscopic study reporting average time to recurrence 
longer than any average follow-up duration of an endoscopic 
study), and given that the average follow-up duration for 
studies reporting on disease recurrence is 1.0–15.4 years 
for microscopy and 1.4–5.9 years for endoscopy, the bias is 
probably not very large.
From a pathophysiological perspective, the similar 
results yielded for microscopic and endoscopic transsphe-
noidal surgery may be explained by the large percentage 
of microadenomas in the population of Cushing’s disease 
patients [109]. For microadenomas, there may not be an 
advantage in increasing field of vision at the cost of los-
ing three-dimensional vision and thereby depth perception 
[6, 8]. Most likely, due to their small size, microadeno-
mas are completely within the field of vision regardless 
of surgical technique. Our results concerning remission 
and recurrence for microadenomas indeed showed no clear 
advantage for either technique. For macroadenomas, we 
did show an advantage of the endoscopic surgical tech-
nique. As macroadenomas are larger and more often inva-
sive, a broader field of vision in close proximity to the 
tumor may aid the neurosurgeon in achieving a complete 
tumor resection, causing higher remission and lower recur-
rence rates after endoscopic surgery. In microscopic sur-
gery, these tumors are more often partially out of vision 
for the neurosurgeon. Unfortunately, due to lack of data, 
we were unable to perform separate analyses for invasive 
vs. non-invasive macroadenomas, as well as for small vs. 
larger microadenomas. The increased rate of cerebrospinal 
fluid leak after endoscopic transsphenoidal surgery may 
partially be explained by the neurosurgeon’s attempt to 
achieve complete tumor resection also in more difficult 
cases with the newer endoscopic technique, whereas the 
reduced rate of transient diabetes insipidus may originate 
from the more precise tumor excision due to improved 
vision close to the tumor, causing less damage to the 
posterior lobe of the pituitary. Publication bias has been 
suggested as partial explanation for the increased rate of 
cerebrospinal fluid leak after endoscopic surgery, as more 
often challenging macroadenomas have been described 
[14].
For most Cushing’s disease patients, this study shows 
no clear advantage of either microscopic or endoscopic 
transsphenoidal surgery regarding surgical outcomes and 
complication rates. For macroadenomas, the endoscopic 
technique yields better results regarding remission and 
recurrence rate. These results are present despite the pre-
sumed learning curve of the newer endoscopic technique 
within the study period, although confounding by indica-
tion and improved radiological investigations with time 
cannot be excluded. As most patients with Cushing’s dis-
ease have microadenomas [109], there is no reason that 
all neurosurgical centers treating patients with Cushing’s 
disease should change to the endoscopic technique. How-
ever, there is also no particular reason to keep using the 
microscopic technique for patients with Cushing’s dis-
ease, other than neurosurgeon’s preference. Based on this 
study, centers that choose to use the microscopic technique 
should consider referral of patients with Cushing’s disease 
and a macroadenoma to another surgical center that per-
forms endoscopic surgery.
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